Weekly Digest – 25-31 Mar 2023 Weekly Digest – 25-31 Mar 2023 31 Mar 2023: Breyanzi (Lisocabtagene Maraleucel) / 2L NHL / BMS: Granted Positive CHMP opinion in EU BMS announced positive CHMP opinion for Breyanzi to treat adult patients […]
Weekly Digest – 25-31 Mar 2023 Weekly Digest – 25-31 Mar 2023 30 Mar 2023: Opdivo (Nivolumab) (IV) / Neoadjuvant NSCLC / BMS: Long-term clinical benefits were observed in 3 years follow up in CheckMate -816 study The CheckMate -816 trial […]
Weekly Digest – 25-31 Mar 2023 Weekly Digest – 25-31 Mar 2023 29 Mar 2023: Osemitamab (TST001) / Pancreatic Cancer / Transcenta: US FDA granted Orphan Drug Designation FDA has granted Orphan Drug Designation to Osemitamab (TST001) for the treatment […]
Weekly Digest – 25-31 Mar 2023 Weekly Digest – 25-31 Mar 2023 27 Mar 2023: KEYTRUDA (Pembrolizumab) (IV) / Stage III-IV or 1L Endometrial Carcinoma / Merck: Improved Progression-Free Survival in Phase 3 trial Merck’s Phase 3 trial results of […]
Weekly Digest – 25-31 Mar 2023 Weekly Digest – 25-31 Mar 2023 27 Mar 2023: Kisqali (Ribociclib) / HR+/HER2- Early Breast Cancer / Novartis: Phase 3 Pivotal NATALEE trial meets primary endpoint of Invasive Disease-free survival Novartis announced encouraging data […]
Weekly Digest – 25-31 Mar 2023 Weekly Digest – 25-31 Mar 2023 27 Mar 2023: Pemazyre Oral/ Myeloid/Lymphoid Neoplasms (MLNs) / Incyte: Received MHLW approval in Japan Pemazyre’s MHLW approval was based on the Phase 2 FIGHT-203 Myeloid/Lymphoid Neoplasms (MLNs) […]
